rts logo

Here is a breakdown of major shareholders in Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI)

Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is 152.49% higher on its value in year-to-date trading and has touched a low of $0.13 and a high of $3.43 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BCLI stock was last observed hovering at around $0.72 in the last trading session, with the day’s loss setting it -0.03%.

Currently trading at $0.69, the stock is 50.42% and 73.88% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.94 million and changing -4.13% at the moment leaves the stock -12.70% off its SMA200. BCLI registered -72.43% loss for a year compared to 6-month gain of 245.17%. The firm has a 200-day simple moving average (SMA200) of -$1.70.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a 88.85% loss in the last 1 month and extending the period to 3 months gives it a 141.86%, and is 4.44% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 21.08% over the week and 18.68% over the month.

Brainstorm Cell Therapeutics, Inc. (BCLI) has around 29 employees, a market worth around $33.76M and $0.00M in sales. Distance from 52-week low is 414.40% and -79.90% from its 52-week high.

Brainstorm Cell Therapeutics, Inc. quarterly earnings per share for the current quarter are estimated at $0.

55 institutions hold shares in Brainstorm Cell Therapeutics, Inc. (BCLI), with institutional investors hold 10.04% of the company’s shares. The shares outstanding are 60.49M, and float is at 40.23M with Short Float at 2.11%. Institutions hold 8.25% of the Float.

The top institutional shareholder in the company is Vanguard Group Inc with over 1.42 million shares valued at $2.93 million. The investor’s holdings represent 3.16% of the BCLI Shares outstanding. As of Jun 29, 2023, the second largest holder is Sabby Management, LLC with 1.27 million shares valued at $2.61 million to account for 2.82% of the shares outstanding. The other top investors are AIGH Capital Management LLC which holds 0.71 million shares representing 1.57% and valued at over $1.46 million, while Susquehanna International Group, LLP holds 1.12% of the shares totaling 0.51 million with a market value of $1.04 million.

Brainstorm Cell Therapeutics, Inc. (BCLI) Insider Activity

The most recent transaction is an insider purchase by Lindborg Stacy, the company’s Co-Chief Executive Officer. SEC filings show that Lindborg Stacy bought 11,500 shares of the company’s common stock on Sep 01 ’23 at a price of $1.77 per share for a total of $20402.0. Following the purchase, the insider now owns 0.18 million shares.

Related Posts